Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

European Notebook: Bayer Bids For Monsanto; Biosimilar Uptake Still Sluggish; EMA Enters Drug Pricing Debate

Executive Summary

The restructuring of business portfolios occupies Europe's big pharma companies, while the region's health providers look to improve the uptake of biosimilars, and European regulators suggest ways to use greater market competition to tame high drug prices. Plus Brexit, trade agreements, pharmacovigilance and more in this month's column.

Advertisement

Related Content

Germany May Make Drug Prices Confidential In AMNOG Update
Changes Brewing At Bayer, But Pharma Strategy Remains On Point
Novartis Rejiggers Pharma To Favor Oncology
Comparing EU Vs. US Accelerated Pathway Approval Times Makes Senior UK Regulator 'Slightly Defensive'
European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register